Search Within

Adult Leukemia

Formats
  1. Meeting Abstract (1797)
  2. Journal Article (1603)
  3. Review (122)
  4. Research Letter (55)
  5. Editorial (49)
  6. Book Section (39)
  7. Guidelines (20)
  8. Conference Paper (18)
  9. Correspondence (13)
  10. Miscellaneous (3)
  11. Book Whole (1)
Groups
  1. Center for Hematologic Malignancies (3720)
  2. Department of Medicine (3689)
  3. Hematologic Malignancies, Division of (3685)
  4. GSK Faculty (1783)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1378)
  6. Executive Committee, Center for Hematologic Malignancies (970)

More Groups

People
  1. Ross Levine (787)
  2. Martin Tallman (655)
  3. David Scheinberg (502)
  4. Jae Park (387)
  5. Eytan Stein (371)
  6. Raajit Rampal (352)

More People

Years
  1. 2025 (103)
  2. 2024 (196)
  3. 2023 (233)
  4. 2022 (255)
  5. 2021 (248)
  6. 2020 (273)

More Years

Publications
  1. Blood (1254)
  2. Journal of Clinical Oncology (217)
  3. Clinical Lymphoma, Myeloma and Leukemia (117)
  4. Leukemia (110)
  5. Haematologica (107)
  6. Cancer Research (86)

More Publications

Publishers
  1. American Society of Hematology (1345)
  2. Nature Publishing Group (324)
  3. Elsevier Inc. (255)
  4. American Association for Cancer Research (234)
  5. American Society of Clinical Oncology (230)
  6. Ferrata Storti Foundation (107)

More Publishers

Results (3720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia
    Journal Article

    Prebet, T.; Goldberg, A. D.; Jurcic, J. G.; Khaled, S.; Dail, M.; Feng, Y.; Green, C.; Li, C.; Ma, C.; Medeiros, B. C.; more...
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Ponatinib after failure of second-generation tyrosine kinase inhibitor in resistant chronic-phase chronic myeloid leukemia
    Journal Article

    Kantarjian, H. M.; Jabbour, E.; Deininger, M.; Abruzzese, E.; Apperley, J.; Cortes, J.; Chuah, C.; DeAngelo, D. J.; DiPersio, J.; Hochhaus, A.; more...
    American Journal of Hematology (2022)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Single-cell multi-omics of human clonal hematopoiesis reveals that DNMT3A R882 mutations perturb early progenitor states through selective hypomethylation
    Journal Article

    Nam, A. S.; Dusaj, N.; Izzo, F.; Murali, R.; Myers, R. M.; Mouhieddine, T. H.; Sotelo, J.; Benbarche, S.; Waarts, M.; Gaiti, F.; more...
    Nature Genetics (2022)

    Fulltext@MSK | Save
  • Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia
    Journal Article

    Parisi, R.; Cowen, E. A.; Stoll, J. R.; Zhu, H.; Dusza, S.; Pulitzer, M. P.; Stein, E. M.; Markova, A.
    Leukemia Research (2022)

    Fulltext@MSK | Save
  • Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling
    Journal Article

    Ganzel, C.; Sun, Z.; Baslan, T.; Zhang, Y.; Gönen, M.; Abdel-Wahab, O. I.; Racevskis, J.; Garrett-Bakelman, F.; Lowe, S. W.; Fernandez, H. F.; more...
    Leukemia Research (2022)

    Fulltext@MSK | Save
  • Phase III MANIFEST-2: Pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis
    Review

    Harrison, C. N.; Gupta, V. K.; Gerds, A. T.; Rampal, R.; Verstovsek, S.; Talpaz, M.; Kiladjian, J. J.; Mesa, R.; Kuykendall, A. T.; Vannucchi, A. M.; more...
    Future Oncology (2022)

    Fulltext@MSK | Save
  • Adding umbralisib and ublituximab (U2) to ibrutinib in patients with CLL: A phase II study of an MRD-driven approach
    Journal Article

    Roeker, L. E.; Feldman, T. A.; Soumerai, J. D.; Falco, V.; Panton, G.; Dorsey, C.; Zelenetz, A. D.; Falchi, L.; Park, J. H.; Straus, D. J.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999
    Research Letter

    Rapaport, F.; Seier, K.; Neelamraju, Y.; Hassane, D.; Baslan, T.; Gildea, D. T.; Haddox, S.; Lee, T.; Murdock, H. M.; Sheridan, C.; more...
    Blood Cancer Journal (2022)

    Fulltext@MSK | Save
  • A matching-adjusted indirect comparison of asciminib versus ponatinib, nilotinib and dasatinib in chronic phase chronic myeloid leukemia patients after ≥2 tyrosine kinase inhibitors
    Meeting Abstract

    Atallah, E. L.; Maheshwari, V.; Mauro, M. J.; Boquimpani, C.; Rea, D.; Hochhaus, A.; Minami, Y.; Saini, L.; Corbin, R.
    Value in Health (2022)

    Fulltext@MSK | Save